Cenobamate May Help Children With Hard-To-Treat Epilepsy

What was studied

This study looked at cenobamate used as an add-on seizure medicine in children, teens, and young adults with drug-resistant epilepsy. It was a retrospective, multicenter real-world study, meaning the researchers reviewed past medical records from pediatric epilepsy referral centers rather than assigning treatment in a trial.

The study included 94 patients ages 0 to 21 years who had taken cenobamate and had at least 6 months of follow-up. Most had difficult-to-treat epilepsy: the median age when epilepsy started was 4.3 years, 72% had developmental delay, and cenobamate was started after a median of 7 previous anti-seizure medicines. The main question was how many patients had at least a 50% drop in seizure frequency at 6 and 12 months. The study also looked at seizure freedom, side effects, how many stayed on the medicine, and whether other seizure medicines could be reduced or stopped.

What they found

At 6 months, 41% of patients had at least a 50% reduction in seizures. At 12 months, this was 54%. The median follow-up was 12 months, and retention was 40%.

Adverse effects were reported in 24% of patients at 6 months. The abstract describes cenobamate as effective and well tolerated, but it does not give details here about which side effects were most common or how severe they were. Doctors also reduced the dose of other anti-seizure medicines in 55% of patients, and 35% had other anti-seizure medicines discontinued.

Limits of the evidence

This was not a randomized trial, so it cannot show on its own that cenobamate caused the seizure improvement. Because it was retrospective, the results depend on what was recorded in medical charts, and some information may have been incomplete.

The study was done in referral centers and included patients with very difficult-to-treat epilepsy, so the results may not apply to all children with epilepsy. The 40% retention rate may make longer-term results harder to interpret. The abstract also does not give full details on seizure freedom rates, side effect types, or how results differed by age group or epilepsy type.

For families and caregivers

For families of children with focal, drug-resistant epilepsy, this study suggests that cenobamate may help some young people when added to other seizure medicines, including younger pediatric patients. It also suggests that some patients had other seizure medicines reduced or discontinued over time.

Still, this is retrospective real-world evidence, not proof from a controlled pediatric trial. Families may want to ask a child’s epilepsy specialist how cenobamate fits with the child’s seizure type, age, other medicines, and side effect risks.

What to watch next

Prospective pediatric studies could help clarify how cenobamate compares with other treatment options and provide more detail on side effects, seizure freedom, and outcomes in different age groups or epilepsy types.

Terms in this summary

adjunctive therapy

A treatment used together with another treatment, not by itself.

drug-resistant epilepsy

Epilepsy that does not come under good control after trying appropriate seizure medicines.

retrospective study

A study that looks back at existing medical records instead of following patients forward from the start.

multicenter study

A study done at more than one hospital or clinic.

focal epilepsy

Seizures that start in one area of the brain.

retention rate

The percentage of patients who are still taking a treatment after a certain amount of time.

anti-seizure medicines

Medicines used to prevent or reduce seizures.

developmental delay

When a child is slower than expected in reaching learning, speech, movement, or social milestones.